Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Melphalan”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT00253721
What this trial is testing

Melphalan With BBBD in Treating Patients With Brain Malignancies

Who this might be right for
Brain and Central Nervous System TumorsLymphomaMetastatic Cancer
OHSU Knight Cancer Institute 21
Testing effectiveness (Phase 2)UnknownNCT00908180
What this trial is testing

Carmustine, Etoposide, Cytarabine, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Lymphoma
Cancer Research UK 47
Testing effectiveness (Phase 2)Study completedNCT01242267
What this trial is testing

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 29
Testing effectiveness (Phase 2)Ended earlyNCT00523809
What this trial is testing

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Who this might be right for
Breast CancerOvarian Cancer
M.D. Anderson Cancer Center 5
Not applicableStudy completedNCT00890552
What this trial is testing

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

Who this might be right for
LeukemiaAmyloidosis
Stanford University 25
Testing effectiveness (Phase 2)Study completedNCT02506959
What this trial is testing

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Plasma Cell LeukemiaPlasmacytomaRecurrent Plasma Cell Myeloma+1 more
M.D. Anderson Cancer Center 83
Testing effectiveness (Phase 2)Study completedNCT00784823
What this trial is testing

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 32
Testing effectiveness (Phase 2)UnknownNCT01923935
What this trial is testing

Busulfan and Melphalan Conditioning in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Chonnam National University Hospital 105
Large-scale testing (Phase 3)Study completedNCT00083915
What this trial is testing

DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation

Who this might be right for
Multiple Myeloma
University of Arkansas 97
Post-approval studies (Phase 4)Study completedNCT06425276
What this trial is testing

Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation

Who this might be right for
Multiple Myeloma
CASI Pharmaceuticals (China) Co., Ltd. 67
Testing effectiveness (Phase 2)Study completedNCT00103298
What this trial is testing

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Who this might be right for
Colorectal CancerMetastatic Cancer
National Cancer Institute (NCI)
Not applicableUnknownNCT03266042
What this trial is testing

Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy

Who this might be right for
Hepatic Malignant Neoplasm Primary Non-Resectable
Delcath Systems Inc. 200
Testing effectiveness (Phase 2)Study completedNCT00883623
What this trial is testing

A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis

Who this might be right for
Primary Amyloidosis
Heidelberg University 50
Early research (Phase 1)Study completedNCT02148913
What this trial is testing

Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Corewell Health West 18
Testing effectiveness (Phase 2)UnknownNCT05084027
What this trial is testing

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

Who this might be right for
Hematologic MalignancyOlder PatientsAllogeneic Hematopoietic Stem Cell Transplantation
First Affiliated Hospital of Zhejiang University 50
Testing effectiveness (Phase 2)Study completedNCT00008268
What this trial is testing

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT01421173
What this trial is testing

Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Lymphoma
M.D. Anderson Cancer Center 78
Testing effectiveness (Phase 2)WithdrawnNCT03328936
What this trial is testing

Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Ohio State University Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00743288
What this trial is testing

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Who this might be right for
Multiple Myeloma
Oncotherapeutics 40
Early research (Phase 1)Study completedNCT00985959
What this trial is testing

JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 101
Next Page